XNAS
SBFMW
Market cap6mUSD
Jun 06, Last price
0.25USD
1D
-20.40%
1Q
53.13%
IPO
-59.17%
Name
Sunshine Biopharma Inc
Chart & Performance
Profile
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 34,874 44.75% | 24,093 454.42% | 4,346 1,802.41% | |||||||
Cost of revenue | 41,627 | 28,439 | 12,939 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (6,752) | (4,346) | (8,594) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (235) | 395 | 233 | |||||||
Tax Rate | ||||||||||
NOPAT | (6,518) | (4,742) | (8,827) | |||||||
Net income | (5,134) 13.94% | (4,506) -83.15% | (26,744) 109.51% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 5,383 | 3,548 | 30,268 | |||||||
BB yield | -255.68% | -53.71% | -311.55% | |||||||
Debt | ||||||||||
Debt current | 208 | 119 | 3,632 | |||||||
Long-term debt | 1,697 | 1,197 | 1,284 | |||||||
Deferred revenue | (43) | |||||||||
Other long-term liabilities | 43 | |||||||||
Net debt | (7,782) | (14,977) | (18,540) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (12,531) | (8,775) | (5,248) | |||||||
CAPEX | (82) | (305) | ||||||||
Cash from investing activities | (2,321) | (656) | (14,619) | |||||||
Cash from financing activities | 9,290 | 3,426 | 39,465 | |||||||
FCF | (13,964) | (5,877) | (12,102) | |||||||
Balance | ||||||||||
Cash | 9,687 | 16,292 | 21,826 | |||||||
Long term investments | 1,630 | |||||||||
Excess cash | 7,943 | 15,088 | 23,239 | |||||||
Stockholders' equity | (69,854) | (63,181) | (59,214) | |||||||
Invested Capital | 94,307 | 85,046 | 84,743 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 702 | 12 | 8 | |||||||
Price | 3.00 -99.45% | 543.00 -57.58% | 1,280.00 -81.75% | |||||||
Market cap | 2,105 -68.13% | 6,606 -32.01% | 9,715 6.06% | |||||||
EV | (5,663) | (8,370) | (8,824) | |||||||
EBITDA | (6,529) | (4,197) | (8,568) | |||||||
EV/EBITDA | 0.87 | 1.99 | 1.03 | |||||||
Interest | 9 | 137 | 39 | |||||||
Interest/NOPBT |